Ligand Pharmaceuticals Incorporated
LGNDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Ligand Pharmaceuticals Incorporated (LGND) is listed under Biotechnology. The $4.61B market capitalization puts LGND squarely in mid-cap range for its industry. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Market Cap
$4.61B
Beta
1.07
P/E (TTM)
29.92
P/E (Fwd)
20.30
EPS (TTM)
$7.68
EPS (Fwd)
$11.32
ROE
17.1%
ROA
5.2%
Cash
$779.4M
Total Debt
$452.0M
Free CF
$142.1M
52W Change
124.5%
Annual Financials
Cash vs Debt
Ligand Pharmaceuticals Incorporated holds $779.4M in cash against $452.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $142.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 17.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $196.2M (2022) to $268.1M (2025), reflecting a 37% increase over the period.
Investors considering Ligand Pharmaceuticals Incorporated should weigh the typical risks associated with LGND's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing LGND's risk profile alongside its fundamentals and technical indicators provides a more complete picture.